Board of Directors
Andy Richards CBE
Dr. Andy Richards CBE is a well-established entrepreneur and builder of biotechnology, healthcare and diagnostic ventures. He brings a strong business focus and an in-depth knowledge of the industry and company scale up. In addition to Abcodia he is also currently Chairman of Congenica and Arecor and a Director of Silence Therapeutics plc, Sensiia , and Ieso Digital Health. He is Chairman of BBT the Babraham Research Campus and a director of Cancer Research Technology Ltd (the commercial arm of Cancer Research UK). His early career spanned positions with ICI (now AstraZeneca) and PA Technology, and he was a founder and executive director of Chiroscience. Andy is a graduate of Cambridge University with a PhD in Chemistry and a track record as a founder, active investor in and director of more than 25 innovative healthcare and life-science companies, including Vectura plc and Arakis Ltd. Andy is also a founder member of the Cambridge Angels.
Julie Barnes, PhD.
Julie has over 30 years experience of the Pharmaceutical and Biotechnology industry. She trained in pharmacology and neuroscience and gained 15 years experience in R&D with GlaxoSmithKline, latterly as head of Neuroscience. From 2001-2009, she was Chief Scientific Officer / Board Director at BioWisdom Ltd, a healthcare technology company providing innovative data solutions for the pharmaceutical industry. Julie has a deep understanding of the healthcare sector, both pharmaceutical R&D, diagnostics and other emerging solutions for better health management. She has spearheaded specific initiatives, including the development of medical imaging techniques for use in early clinical trials, assessment of safety liability in pharmaceutical products, creation of novel informatics solutions to support R&D, and delivered innovative diagnostic solutions for better healthcare. In 2013, she won the WISE (Women in Science and Engineering) Award for Enterprise and Innovation award by HRH The Princess Royal.
Chris has over 20 years’ experience in finance and has held senior positions at a variety of organization types, ranging from business start-ups to a FTSE 250 company. He joined Abcodia as CFO in October 2015. Before joining the company Chris was CFO at Zinwave Ltd, steering the company to its sale in 2014. He was the Finance Director at Enecsys Ltd. and played a fundamental role in numerous fund raising activities, (including Series B for $41m) to support the global growth of the organization.
Andrew is lead healthcare partner at Albion Ventures. Following biomedical research, he qualified as a surgeon, specializing in neurosurgery. He then joined the Boston Consulting Group (BCG) where he specialized in healthcare strategy, gaining experience with many large, global clients across the full spectrum of healthcare including biotechnology, pharmaceuticals, service and care providers, software and telecommunications. He oversees Albion Ventures’ broad range of healthcare investing, from care provision to life science services, imaging and diagnostics.
Jan is a Partner and member of the investment committee at Scottish Equity Partners (SEP), where she leads investments in high growth technology companies and oversees investments across the healthcare sector. A venture capital investor for the past 15 years, Jan joined SEP in 2004 from Dresdner Kleinwort Capital. Prior to moving into the investment field, she held operational and commercial roles in the pharmaceutical industry for, Merck, Novartis and Quintiles.
Robert joined Cambridge Innovation Capital as the Investment Director for Life Sciences in January 2014 after 20 years’ experience in the pharma/biotech industry working both at large pharma (Sanofi, Roche), the MHRA and in VC backed companies (Arakis, KalVista) including founding the malaria therapeutics company Treague and as founding CEO of Avilex Pharma. Robert qualified in medicine at University College London; he is a member of the Royal College of Obstetricians and Gynecologists and the Faculty of Pharmaceutical Medicine. He has an MBA from London Business School and an MPhil in Biostatistics from the University of Cambridge.
Richard A. Sandberg
Dick has played a principal role in starting and building a number of medical diagnostic companies including that of founder, chairman, chief executive officer, and chief financial officer of DIANON Systems Inc.. He also served as chairman and chief financial officer of Lifecodes Corporation, a pioneer in DNA testing technology; chief financial officer and director of Matritech Inc., a company specializing in proteomic diagnostic products for the early detection of a variety of cancers. He is currently the Chairman of Oxford Immunotec a global diagnostics company providing advanced, innovative tests in the field of immunology.
Professor Ian Jacobs
Ian has an international reputation for his work in screening for ovarian cancer over the last 20 years. He has over 100 original peer reviewed publications and alongside his clinical role in gynaecological oncology directs a laboratory and clinical research team of over 100 staff at University College London and further afield, focused on molecular genetics, proteomics, biomarkers, prevention and screening for gynaecological cancer. He is the lead investigator for the UK Collaborative Trial of Ovarian Cancer Screening from which the serum biobank was founded.